Metagenomi Therapeutics, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$25M
R&D
$94M
D&A
$5M
Operating Income
$-96M
EBITDA
$-91M
Interest Income
$9M
Other Income/Expense
$-1M
Pretax Income
$-88M
Tax Provision
$-58K
Net Income
$-88M
Operating Margin
-380.9%
Net Margin
-348.5%
Effective Tax Rate
0.1%
Deferred Tax Liabilities
$2M
DTA Valuation Allowance
$92M
Tax Credit Carryforwards
$8M
NOL Carryforwards
$52M
ETR (Continuing Operations)
0.1%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.4%
Operating Lease Cost
$10M
Revenue YoY Variation
-51.8%
Income YoY Variation
-8.0%